WIRE - Novel Treatments in Renal Cell Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Renal Cell Cancer
Interventions
DRUG

Olaparib

Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5

DRUG

Cediranib

Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3

DRUG

Durvalumab

Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy

Trial Locations (2)

CB2 2QQ

RECRUITING

Addenbrooke's Hospital, Cambridge

Unknown

RECRUITING

Beatson Institute for Cancer Research, Glasgow

Sponsors
All Listed Sponsors
collaborator

University of Cambridge

OTHER

collaborator

AstraZeneca

INDUSTRY

collaborator

Cancer Research UK

OTHER

lead

CCTU- Cancer Theme

OTHER